Emkay Global Financial's research report on ICICI Pru Life
IPRU reported relatively weaker performance in H1FY24, wherein the negative surprise on VNB margin (28.8% vs Emkay: 30%) added to the challenge of the persistent weak growth (0.1% YoY vs Emkay: 2.6% YoY). Although the correct measures are being undertaken by Management for resurrecting top-line growth, these will take time to bear fruit; however, any positive outcome will be preceded by surge in costs. Additionally, we foresee some growth challenges emerging in the non-ICICIB banca channel, beset by a higher base and addition of new life insurers.
Outlook
Overall, we see the growth & margin concerns sticking (except in Q3FY24, when the lower base would be favorable for growth). Accounting for such developments, we cut our FY24-26E APE by ~5% and VNB by ~7%; we downgrade the stock to HOLD from Buy, with revised Sep-24E TP of Rs 610/share (implied FY25 P/EV: 1.8x).
For all recommendations report, click here
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.